Analyzes of Hemorrhagic Obstetric Patients Whose Were Used Fibrinogen
Treatment of Obstetric Hemorrhage With Fibrinogen and Blood Products: Retrospective Analyzes
1 other identifier
observational
56
1 country
1
Brief Summary
The files of hemorrhagic obstetric patients undergoing surgery and followed in the intensive care unit and using Fibrinogen and blood products were included in the study between January 2015- September 2018 at the Anesthesiology and Reanimation Clinic of SBU Kanuni Sultan Süleyman Training and Research Hospital. Patients under 18 years of age were excluded from the study. In this study, ages, operation types, number of blood and products, the amount of fibrinogen, the results of the hemogram and bleeding parameters, the levels of fibrinogen, the duration of hospital stay and the intensive care unit were recorded.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Oct 2018
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 9, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 16, 2018
CompletedFirst Submitted
Initial submission to the registry
October 24, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
October 24, 2018
CompletedFirst Posted
Study publicly available on registry
October 29, 2018
CompletedOctober 30, 2018
October 1, 2018
7 days
October 24, 2018
October 26, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
Measurement of fibrinogen (mg/L)
Significant independent predictor for evolution to severe PPH was plasma fibrinogen level.
24 hours
Measurement of hemoglobin (g/dL)
Postpartum hemorrhage (PPH) is a major contributor to maternal death and severe maternal morbidity
24 hours
Amount of fibrinogen consantrates
in order to avoid PPH
24 hours
Amount of blood products (unit)
degree of hemorrhagie
24 hours
Secondary Outcomes (1)
Hospital stay days
24 hours
Interventions
Fibrinogen and blood products
Eligibility Criteria
\- Obstetric patients who underwent surgery and followed in ICU and Used Fibrinogen and Blood products in peroperatively or postoperatively
You may qualify if:
- Obstetric patients, underwent surgery and followed in ICU
- Used Fibrinogen and Blood products
- Over 18 years age
You may not qualify if:
- Under 18 years age
- Obstetric patients, underwent surgery but not used Fibrinogen and Blood products
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Kanuni Sultan Suleyman Education and Training Hospital
Istanbul, Kucukcekmece, 34306, Turkey (Türkiye)
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ayca Sultan Sahin, MD
Kanuni Sultan Suleyman Education and Training Hospital
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
October 24, 2018
First Posted
October 29, 2018
Study Start
October 9, 2018
Primary Completion
October 16, 2018
Study Completion
October 24, 2018
Last Updated
October 30, 2018
Record last verified: 2018-10